Trial · NCT02124746
Outcomes11
Each outcome the trial posted results for, in ClinicalTrials.gov's words.
1 to 11 of 11
Download this page as JSON| Type | Outcome | Time frame | Population | Units | Measured as |
|---|---|---|---|---|---|
| PRIMARY | Long Term Safety and Tolerability as Measured by the Incidence and Severity of Adverse Events and Clinical Laboratory Abnormalities | From the first dose of momelotinib in the parent study to 30 days following permanent discontinuation of momelotinib in Study GS-US-352-1154. | It was pre-specified that safety outcomes would be analyzed and summarized by starting dose in Study GS-US-352-1154. Therefore data for this outcome measure are presented for the total subjects enrolled to Study GS-US-352-1154 and not by cohort. | Participants | COUNT_OF_PARTICIPANTS |
| SECONDARY | Splenic Response Rate | From baseline in the parent study until the last spleen assessment in Study GS-US-352-1154, up to 30 days following permanent discontinuation of momelotinib. | Subjects with splenomegaly \>5 cm at baseline in the parent studies who were enrolled in Study GS-US-352-1154 were evaluable for splenic response assessment. | Participants | COUNT_OF_PARTICIPANTS |
| SECONDARY | Duration of Splenic Response | From baseline in the parent study until the last spleen assessment in Study GS-US-352-1154, up to 30 days following permanent discontinuation of momelotinib. | Duration of splenic response was assessed for spleen responders who enrolled in Study GS-US-352-1154 only. | days | MEDIAN |
| SECONDARY | Transfusion Independence Response Rate | From baseline in the parent study until the last assessment in Study GS-US-352-1154, up to 30 days following permanent discontinuation of momelotinib. | Subjects who were transfusion dependent at baseline in the parent studies and were enrolled in Study GS-US-352-1154 were evaluable for transfusion independence response. | Participants | COUNT_OF_PARTICIPANTS |
| SECONDARY | Duration of Transfusion Independence Response | From baseline in the parent study until the last assessment date in Study GS-US-352-1154, up to 30 days following permanent discontinuation of momelotinib. | Duration of transfusion independence response was assessed for transfusion independence responders who were enrolled in Study GS-US-352-1154. | days | MEDIAN |
| SECONDARY | Anemia Response Rate | From baseline in the parent study until the last assessment in Study GS-US-352-1154, up to 30 days following permanent discontinuation of momelotinib. | Subjects who were anemia response-evaluable at baseline in the parent studies and were enrolled in Study GS-US-352-1154 were evaluable for anemia response. | Participants | COUNT_OF_PARTICIPANTS |
| SECONDARY | Duration of Anemia Response | From baseline in the parent study until the last assessment in Study GS-US-352-1154, up to 30 days following permanent discontinuation of momelotinib. | Duration of anemia response was assessed for anemia responders who were enrolled in Study GS-US-352-1154. | days | MEDIAN |
| SECONDARY | Rate of RBC Transfusion | From the first dose of momelotinib in the parent study until the last dose of momelotinib in Study GS-US-352-1154. | It was pre-specified that safety outcomes would be analyzed and summarized by starting dose in Study GS-US-352-1154. Therefore data for this outcome measure are presented for the total subjects enrolled to Study GS-US-352-1154 and not by cohort. | RBC units per month | MEDIAN |
| SECONDARY | Overall Survival | From baseline in the parent study until the date of last contact or last response assessment, up to 30 days following permanent discontinuation of momelotinib. | months | MEDIAN | |
| SECONDARY | Progression-Free Survival | From baseline in the parent study until the last response assessment, up to 30 days following permanent discontinuation of momelotinib. | months | MEDIAN | |
| SECONDARY | Leukemia-Free Survival | From baseline in the parent study until the date of the last assessment, up to 30 days following permanent discontinuation of momelotinib. | months | MEDIAN |
Source ClinicalTrials.govtrials-2026-11-12-0.5.0
Sources 3
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ClinicalTrials.govNo license stated
- NIH RePORTER's clinical studies and project filesPublic domain
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ClinicalTrials.govnone stated
- NIH RePORTER's clinical studies and project filesPublic domain (NIH RePORTER)
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this list from software.
Twenty rows a page, as JSON. No key.
GET https://conductscience.org/api/trials/v1/NCT02124746/outcomes